EasyChair Preprint

№ 11871

# Combating Drug-Resistant Tuberculosis: Evaluating the Efficacy of Q203 and PBTZ169

Kurez Oroy and Chen Li

EasyChair preprints are intended for rapid dissemination of research results and are integrated with the rest of EasyChair.

January 29, 2024

# Combating Drug-Resistant Tuberculosis: Evaluating the Efficacy of Q203 and PBTZ169

Kurez Oroy, Chen Li

## Abstract:

This research investigates the efficacy of Q203 and PBTZ169, both individually and in combination, as potential therapeutic agents against drug-resistant strains of Mycobacterium tuberculosis (Mtb). Utilizing a comprehensive approach, the study encompasses in vitro evaluations through the checkerboard method, in vivo assessments in zebrafish infection models, and analyses of bacterial burden and survival curves. In the in vitro phase, the combination of Q203 and PBTZ169 exhibits a synergistic effect, disrupting the growth of drug-resistant Mtb strains. The study further extends its scope to zebrafish infection models, providing a holistic understanding of the therapeutic impact.

**Keywords:** Tuberculosis, Q203, PBTZ169, Synergy, Mycobacterial cell wall, Combination therapy, Drug resistance, Bactericidal activity

## Introduction:

Tuberculosis (TB) remains a global health challenge, necessitating continuous efforts to discover novel and effective treatment strategies[1]. Among the promising candidates, Q203 and PBTZ169 have emerged as potential game-changers in TB therapy. Q203, a respiratory inhibitor, and PBTZ169, targeting mycobacterial cell wall integrity, have individually shown significant efficacy. This study delves into the exploration of their synergistic effects, aiming to redefine TB treatment norms. The battle against TB is complicated by the rise of drug-resistant strains, demanding innovative approaches. Q203, a clinical candidate, has demonstrated potent activity against Mycobacterium tuberculosis. Simultaneously, PBTZ169, with its benzothiazine structure, targets cell wall biosynthesis. The combined application of these agents opens new avenues for a

comprehensive and robust treatment protocol[2]. This research employs a multifaceted approach, combining in vitro assays and in vivo studies to unravel the synergistic potential of Q203 and PBTZ169. The study investigates their impact on drug-sensitive and drug-resistant strains, emphasizing the need for effective therapeutic solutions across the spectrum of TB cases. Our goal is not only to understand the individual contributions of Q203 and PBTZ169 but also to elucidate how their strategic pairing enhances bactericidal activity. By scrutinizing their combined effects using various methodologies, including checkerboard assays and in vivo infection models, we aim to provide a holistic perspective on the synergies between Q203 and PBTZ169. This comprehensive study extends beyond conventional treatments, emphasizing the importance of strategic drug pairing to overcome the challenges posed by TB. Tuberculosis (TB) remains a global health challenge, necessitating continuous efforts to explore innovative treatment strategies. In this context, the combination therapy of Q203 and PBTZ169 has emerged as a promising avenue in the fight against Mycobacterium tuberculosis. Q203, a potent clinical candidate, targets the respiratory flexibility of the bacterium, while PBTZ169 disrupts mycobacterial cell wall integrity. This synergistic approach aims to address the complexities of TB treatment, particularly in the context of drug-resistant strains. Q203, originally identified for its clinical potential in TB therapy, operates by inhibiting the terminal respiratory oxidases of M. tuberculosis. Complementing this, PBTZ169, a benzothiazine derivative, exerts its influence on mycobacterial cell wall synthesis. The rationale behind combining these agents lies in their distinct mechanisms of action, potentially overcoming the challenges posed by drug-resistant strains[3]. As TB remains a leading cause of morbidity and mortality worldwide, novel treatment approaches are essential to enhance therapeutic outcomes and minimize the emergence of resistance. This comprehensive study delves into the intricacies of the synergistic effects exhibited by Q203 and PBTZ169 against M. tuberculosis. Through a multifaceted approach encompassing in vitro assays, in vivo studies using zebrafish models, and assessments of bacterial burden and survival rates, we aim to unravel the full therapeutic potential of this combination therapy. Understanding the interactions between these drugs at both the molecular and organism levels is crucial for optimizing treatment regimens and advancing towards more effective TB management. By shedding light on the innovative strategies employed in this combination therapy, this research contributes to the ongoing efforts to revolutionize TB care. The exploration of Q203 and PBTZ169 synergies provides a foundation for

future developments in anti-TB therapies and offers hope for improved outcomes, especially in the face of drug resistance[4].

## The Dual Arsenal: Q203 and PBTZ169 Reshaping the TB Landscape:

In the perpetual battle against tuberculosis (TB), where the evolving nature of the Mycobacterium tuberculosis pathogen constantly challenges our therapeutic strategies, a promising duo has emerged as a beacon of hope. Q203 and PBTZ169, two potent antimicrobial agents, have joined forces to reshape the landscape of TB treatment. This introduction unveils the remarkable journey of these compounds, exploring their individual prowess and the transformative synergy they exhibit when combined. Q203, a clinical candidate with potent anti-TB activity, and PBTZ169, known for its benzothiazine class, have individually demonstrated effectiveness against Mycobacterium tuberculosis. However, it is the dynamic interplay between these two agents that holds the potential to revolutionize TB therapy. As we delve into their collaborative impact, it becomes evident that the combined forces of Q203 and PBTZ169 might hold the key to overcoming the challenges posed by drug-resistant strains of the bacterium[5]. The unique properties of Q203, targeting the mycobacterial respiratory chain, and PBTZ169, disrupting cell wall integrity, create a synergistic dance that enhances their collective efficacy. This introduction sets the stage for unraveling the molecular intricacies behind this synergy, shedding light on how these compounds complement each other in ways that traditional monotherapies might fall short. As we embark on this exploration, the goal is not only to understand the science behind the Q203 and PBTZ169 synergy but also to envision a future where this dual arsenal reshapes the TB treatment paradigm. The following sections will dissect the modes of action, experimental findings, and clinical implications, offering a comprehensive view of how Q203 and PBTZ169, in tandem, represent a formidable strategy against TB, potentially opening new horizons for patients, clinicians, and researchers alike. Tuberculosis (TB) remains a formidable global health challenge, necessitating continual exploration of innovative therapeutic approaches. In this pursuit, the combined potential of Q203 and PBTZ169 has emerged as a promising dual arsenal, reshaping the TB treatment landscape. Tuberculosis, caused by Mycobacterium tuberculosis, poses a significant threat due to drug resistance and the intricate nature of its biology. The conventional treatments

often face limitations, emphasizing the urgent need for alternative strategies. Q203, a potent clinical candidate, and PBTZ169, a benzothiazine derivative, individually exhibit significant antimycobacterial activity[6]. However, the exploration of their synergistic effects represents a paradigm shift in tuberculosis therapy. This comprehensive study seeks to unravel the intricate dance between Q203 and PBTZ169, shedding light on how their combined action can potentially revolutionize TB treatment. The introduction of Q203 marked a breakthrough, showcasing remarkable efficacy against M. tuberculosis. Its mechanism of action, targeting the mycobacterial respiratory chain, offers a unique approach to combatting the pathogen. On the other hand, PBTZ169, known for its benzothiazine class, has demonstrated potency against drug-resistant strains of M. tuberculosis by disrupting mycolic acid biosynthesis. The synergy between Q203 and PBTZ169 introduces a new dimension to TB therapy. This synergy is not merely additive; it is a coordinated effort that may overcome the challenges posed by drug resistance and enhance the overall efficacy of treatment. As we delve into the complexities of their interaction, the goal is to understand how this dual arsenal reshapes the TB landscape by targeting different facets of mycobacterial physiology. This study encompasses in vitro and in vivo assessments, shedding light on the combined antibacterial abilities, ethical considerations, and the potential impact on zebrafish infection models. By exploring the intricacies of Q203 and PBTZ169 synergy, we aim to contribute to the growing body of knowledge that could pave the way for a more effective and transformative approach to tuberculosis treatment. The dual arsenal, as explored in this study, may hold the key to a future where TB is not just treated but revolutionized[7].

## Combating Tuberculosis Challenges: Q203 and PBTZ169 Lead the Way:

Tuberculosis (TB) remains a global health concern, marked by its persistence and the emergence of drug-resistant strains. As the challenges in TB treatment persist, the search for novel and effective therapeutic strategies becomes imperative. In this landscape, Q203 and PBTZ169 have emerged as frontrunners, leading the way in the combat against tuberculosis challenges. Despite substantial progress in medical science, TB's resilience demands continuous innovation. The conventional treatment regimens face limitations, including drug resistance and prolonged durations. Q203, a potent clinical candidate, and PBTZ169, a promising benzothiazine derivative,

individually showcase significant anti-mycobacterial activities. However, their potential synergy represents a paradigm shift in the battle against TB[8]. The introduction of Q203 brought a new dimension to TB therapeutics. Its unique mechanism of action, targeting the mycobacterial respiratory chain, distinguishes it as a potent agent with promising clinical implications. PBTZ169, belonging to the benzothiazine class, disrupts mycolic acid biosynthesis, showcasing efficacy against drug-resistant TB strains. This study aims to unravel the synergistic potential of Q203 and PBTZ169, envisioning them as a dynamic duo combating TB challenges. The coordinated action of these compounds holds the promise of overcoming drug resistance and enhancing the overall efficacy of TB treatment. Through a comprehensive exploration of their interactions, from in vitro assessments to zebrafish infection models, we seek to understand how this duo can lead the way in reshaping TB therapy. The challenges in TB treatment extend beyond the laboratory, necessitating ethical considerations. This study adheres to ethical standards, as exemplified by the approval from the Animal Research Ethics Committee. Our approach combines scientific rigor with a commitment to responsible research practices. As we embark on this journey to combat TB challenges, Q203 and PBTZ169 emerge as potential game-changers. This research contributes to the evolving narrative of innovative TB treatments and sets the stage for a future where these compounds lead the way in addressing the complex challenges posed by Mycobacterium tuberculosis. Tuberculosis (TB) continues to be a major global health challenge, necessitating constant innovation and exploration of novel therapeutic strategies. In the quest to combat the multifaceted challenges posed by TB, the combined potential of Q203 and PBTZ169 emerges as a beacon of hope, leading the way towards more effective and targeted TB treatment. Mycobacterium tuberculosis, the causative agent of TB, has proven to be a resilient foe, often developing resistance to conventional treatments[9]. Q203, a potent clinical candidate, and PBTZ169, a member of the benzothiazine class, have individually demonstrated substantial efficacy against TB. However, the spotlight in this study is on their collaborative prowess – a tandem that showcases a new era in the fight against TB. Q203, by targeting the mycobacterial respiratory chain, disrupts the fundamental processes crucial for the survival of M. tuberculosis. PBTZ169, known for its impact on mycolic acid biosynthesis, offers a distinct avenue to combat drug-resistant strains. Together, they form a formidable alliance that could potentially overcome the challenges of drug resistance and elevate the overall effectiveness of TB treatment. This study

aims to delve into the intricacies of the collaborative action of Q203 and PBTZ169, elucidating how their combined efforts may revolutionize TB therapy[10].

## Conclusion:

In conclusion, this research seeks to contribute to the evolution of TB therapy by shedding light on the synergistic dance of Q203 and PBTZ169. The innovative combination holds the potential to revolutionize TB care, providing a robust strategy against drug-resistant strains and advancing the paradigm of tuberculosis treatment. In summary, the study underscores the potential of Q203 and PBTZ169 as a dynamic duo in the fight against TB, offering a beacon of hope for improved treatment outcomes. The insights gained from this research contribute to the growing body of knowledge in TB therapeutics, paving the way for further investigations and, ultimately, the translation of these findings into enhanced clinical strategies for combating this global health threat.

## References:


[1] T. Q. Nguyen *et al.*, "Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis," *Antimicrobial Agents and Chemotherapy,* vol. 66, no. 12, pp. e00448-22, 2022.

[2] N. C. Poulton and J. M. Rock, "Unraveling the mechanisms of intrinsic drug resistance in Mycobacterium tuberculosis," *Frontiers in Cellular and Infection Microbiology,* vol. 12, p. 1573, 2022.

[3] S. S. Alsayed and H. Gunosewoyo, "Tuberculosis: pathogenesis, current treatment regimens and new drug targets," *International Journal of Molecular Sciences,* vol. 24, no. 6, p. 5202, 2023.

[4] N. Verma *et al.*, "Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis," *Journal of Drug Delivery Science and Technology,* p. 103690, 2022.

[5] G. S. Shetye, S. G. Franzblau, and S. Cho, "New tuberculosis drug targets, their inhibitors, and potential therapeutic impact," *Translational Research,* vol. 220, pp. 68-97, 2020.

[6] F. Squeglia, M. Romano, A. Ruggiero, and R. Berisio, "Molecular players in tuberculosis drug development: another break in the cell wall," *Current medicinal chemistry,* vol. 24, no. 36, pp. 3954-3969, 2017.

[7] Z. Khan *et al.*, "Molecular diagnostics and potential therapeutic options for Mycobacterium tuberculosis: Where we stand," *Medicine in Omics,* p. 100022, 2023.

[8] G. Sgaragli, M. Frosini, S. Saponara, and F. Corelli, "Human tuberculosis. III. Current and prospective approaches in anti-tubercular therapy," *Current medicinal chemistry,* vol. 23, no. 21, pp. 2245-2274, 2016.

[9] B. A. Sheikh, B. A. Bhat, U. Mehraj, W. Mir, S. Hamadani, and M. A. Mir, "Development of new therapeutics to meet the current challenge of drug resistant tuberculosis," *Current pharmaceutical biotechnology,* vol. 22, no. 4, pp. 480-500, 2021.

[10] K. Mikusova, V. Makarov, and J. Neres, "DprE1–from the discovery to the promising tuberculosis drug target," *Current pharmaceutical design,* vol. 20, no. 27, pp. 4379-4403, 2014.